An $86m equity investment in Sinovac Biotech by a consortium of investors.

Synopsis

An $86m equity investment in Sinovac Biotech, a biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases, by Vivo Capital, Prime Success and Advantech Capital.

Principals

target

Sinovac Biotech

bidder

Advantech Capital

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy